PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 09/699,131 10/706,659 **Application Number** INFORMATION DISCLOSURE Filing Date 10/26/2000 STATEMENT BY APPLICANT First Named Inventor Joseph L. Witztum **Group Art Unit** Unknown 1641 (use as many sheets as necessary) **Examiner Name** Unknown L.Cook 3 **2**/ Sheet of **Attorney Docket Number** 6627-PA0045 **U.S. PATENT DOCUMENTS** U.S. Patent Document Date of Publication of Examiner Name of Patentee or Applicant **Cited Document** Initials* Kind Code² Number of Cited Document MM-DD-YYYY (If known) WC 5,330,910 1 Young et al. 07-19-1994 LYC 2 5,460,947 Young et al. 10-24-1995 FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of Examiner Cite Name of Patentee or Applicant T Cited Document Initials' No. Office³ Number4 Kind Code⁵ of Cited Document MM-DD-YYYY (if known) LYC 3 WO 98/21581 Tsimikas et al 05-22-1998

Dat Considered

Examiner Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ²Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ³Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE offscion of Information unless it contains a write CARP contains.

Under the	Paperv	vork Reduction A	ct of 1995,	no perso	ns are requ	lired to respond to a collection of	information unless it or	ontains a valid OMB	control nun
		•			•		omplete if Know	/n	
Substitute for	form 144	19B/PTO				Application Number 09/699,131 (4) 7-06,0			<i>659</i>
INF	QRM	ATION D	ISCĽO	SUR	E	Filing Date	Octobe	r 26, 2000	
STA	STATEMENT BY APPLICANT					First Named Inventor	Joseph	L. Witztum	
(use as many sheets as necessary)						Group Art Unit	Unknov	n 1641	
						Examiner Name	Unknow	in L.Cook	< '
Sheet		2 of 32 Attorney Docket Number 6627-PA0045				A0045			
			OTHER P	RIOR A	RT - NO	N PATENT LITERATURE D	OCUMENTS		
Examiner Initiats*	Cite No.1	Include na magazine,	me of the a journal, seri	uthor (in ial, symp	CAPITAL I oslum, cata	LETTERS), title of the article (what alog, etc.), date, page(s), volume country where published.	en appropriate), title of Issue number(s), publi	the Item (book, sher, city and/or	T ² .
WC,	4	Hörkkö, S., oxidized pho LDL. J. Clin	ospholipic	is: reco	gnition o	Antiphospholipid antibodie f cardiolipin by monoclonal i.	es are directed againg antibodies to epito	inst epitopes of opes of oxidized	7
	5	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. <i>Science</i> . 1989;246:1275-1281.							
	6	Palinski, W. lipoproteins plasma. J.	from apo	E-defic	cient mice	Cloning of monoclonal auto e. Demonstration of epitop 814.	pantibodies to epito es of oxidized LDL	pes of oxidized in human	
	7	Natural antil	bodies wt	ih the T	15 idioty	, Curtiss, L.K., Palinski, W. pe may act in atherosclero 105:1731-40, 2000.	, Silverman, G.J. a sis, apoptotoc clea	nd Witztum, J.L. rance, and	,
	8	Tsimikas S, Palinski W, Halpem SE, Yeung DW, Curtiss LK, Witzturn JL. Radiolabeled MDA2, an oxidation-specific, Mab, identifies native atherosclerotic lesions in vivo. <i>J Nucl Cardiol</i> . 1999;6:41-53.					•		
LYC.	9	Wu CC, Chang SW, Chen MS, Lee YV. Early change of vascular permeability in hypercholesterolemic rabbits. <i>Arterioscler Thromb Vasc Biol.</i> 1995;15:529-533.							
					;				
·			<u>,.</u>			dicari	·		
					Ü,	W.			
				.		· · · · · · · · · · · · · · · · · · ·	<u>`</u>		
			- //	2 /					
Examiner		Risa	1. X C	erd !			Date Considered	1/8/06	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute form 1449/PTO		Complete if Known		
	Applicati n Number	09/699,131 19/206,659		
INFORMATION DISCLOSURE	Filing Dat	10/26/2000		
STATEMENT BY APPLICANT	First Named Inventor	Joseph L. Witztum		
(Use as many sheets as necessary)	Art Unit	1641		
(ose as many should as necessary)	Examiner Name	Lisa V. Cook		
Sheet # 3 of # 3	Attorney Docket Number	6627-PA0045		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WC.	10	Libby, P. et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine, Vol. 8, No. 11, 1257-1262, Nov. 2002	
	11	Narula, J., et al. Strategic targeting of atherosclerotic lesions. Journal of Nuclear Cardiology, Part 1, pp. 81-90, Jan./Feb. 1999	
ЦC	12	Strauss, H.W. Imaging of atherosclerosis – A worthy challenge. Journal of Nuclear Cardiology, Vol. 3, No. 3, pp. 278-280, May/June 1996	
		Dupilicalt	

Examiner Signature	Cock	Date Considered	1/8/06
Cignaturo / /	·	Considered	,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

MAR 2 9 200 Un

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known						
Application Number	10/706,659					
Filing Date	11/12/2003					
First Named Inventor	WITZTUM et al					
Art Unit	unknown 1641					
Examiner Name	unknown L. Cook					
Attorney Docket Number	6627-P0045D					

			U. S. PATENT	DOCUMENTS	
Examiner initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f Innom)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
WC.	1	^{US-} 5,330,910	7-19-1994	Young et al	whole document
	2	^{US-} 5,460,947	10-24-1995	Young et al	whole document
U/C	3	US- 6,375,925		Witztum et al	whole document
		US-			
	<u> </u>	US-			
		US-			

		FOREIG	N PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ "Number ⁴ "Kind Code ⁶ (if known)	MM-DD-YYYY			T°
LVC	4	WO/98/21581	5-22-1998	Tsimikas et al	whole document	
LYC.	5	WO 94/23302	10-13-1994	Selley	whole document	
		,				
	ļ				ļ	_
	 		_			ļ.,
	ı		i		1	

Examiner Signature	. & Cock	Date Considered	1/8/06
ACTUAL CONTRACTOR AND ADDRESS OF THE PARTY O		AL MOCO COO Barrier Manuals	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Sether Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO			Complete if Known		
, Judouru	10 10 10 11 14 10 10			Application Number	10/706,659	
INF	ORMATION	DIS	CLOSURE	Filing Date	11/12/2003	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	WITZTUM et al	
	// to a manual and	- 4		Art Unit	unknown 1641	
(Use as many sheets as necessary)				Examiner Name	unknown L. Cook	
Sheet	2	of	3	Attorney Docket Number	6627-P0045D	

	-	NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
LYC 6		Hoorko S. Miller, E. Dudl E. et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids:recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. J. Clin. Invest.;1996:98; 815-825				
		Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkövic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. Science . 1989;246:1275-1281				
	Palinski W. Horkko, S. Miller et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins for apo E-deficient mice. Demostration of epitopes of oxidezed LDL in human plasma. J.Clon.Invest 1996;98:800-814					
Shaw P.X, Horkko, S. Chang, M-K Curtiss, L.K. Palinski, W. Silverman, G.J. and Witztum, J.L. Nature antibodies with T15 idiotype may act in atheosclerosis, apoptotoc clearance and protective immunity Clin, Invest. 105:1731-40, 2000						
	10	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholoesterloemic rabbits. Arterioscler Thomb Vasc Biol. 1995, 15-529-533				
	11	Libby P. et al. Stabilizing of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine. Vol 8, No. 11, 1257-1262-Nov. 2002				
	12	Narula, J. et al. Strategic targeting of atherosclerotic lesions. Journal of Nucelar Cardiology, Part 1, pp. 81-90 Jan./Feb 1999				
	13	Strauss, H.W. Imaging of atheosclerosis-A worthy challenge. Journal of Nucelar Cardiology, Vol 3, No 3, pp.278-280 May/June 1996				
	14	Tsimikas, S. et al. In vivo uptake of Radiolabeled MDA2, an oxidation-specific monoclonal antibody provides an accurate measureArterioscler Thromb, Vasc. Biol., Vol 20:689-697.2006				
LVC	15	Holovet, P. et al, Monodialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin Invest. Vol 95:2611-9. 1995				

				-	
Examiner	0,00	$\overline{\mathcal{A}}$	Coll	Date	1/0/04
Signature	Gesa	· /	(80)	Considered	7 ° 7 ° 6

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. 1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/		X 01 1000 110 porson o a.	Complete if Known			
Substitute for form 1443	F 10		Application Number	10/706,659		
INFORMATI	ON DIS	CLOSURE	Filing Date	11/12/2003		
STATEMEN	T BY A	PPLICANT	First Named Inventor	WITZTUM et al		
(the se may	ny sheets as n	ooogga n d	Art Unit	unknown	1641	
(Ose as mai	ny sneeus as n	ecessary)	Examiner Name	unknown	L.COOK	
Sheet 3	of	3	Attorney Docket Number	6627-P0045D		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
WC	16	Tsimikas S. Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific Mab, identifies native atherosclerotic lesions in vivo. J. Nucl Cardiol. 1999; 6:41-53			
 ,					

Examiner Signature	Olisa. X Cont	Date Considered	1/8/06
		1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.